Inclusion Criteria:

          1. Are aged 18 or older.

          2. Have serum EGF concentration >250 pg/ml determined from sample taken at screening.

          3. Have wild type EGF-R sequence.

          4. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          5. Have adequate bone marrow, liver and renal function, as assessed by the Investigator.
             A sample taken at Screening should confirm that:

               -  White blood cell (WBC) count ≥ 3000 per µL

               -  Platelet count ≥ 100,000 per µL

               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x upper
                  limit of normal (ULN) (or ≤ 5 x ULN when liver metastases are present)

               -  Total bilirubin ≤ 1.5 x ULN

               -  Serum creatinine ≤ 1.5 x ULN

          6. Have histologically and/or cytologically confirmed diagnosis of NSCLC, corresponding
             to locally and regionally advanced inoperable disease (Stage IV [as defined by the
             American Joint Committee on Cancer staging system- TNM 7th edition 2010]) excluding
             brain metastases.

          7. Are eligible to receive first-line chemotherapy (without concurrent radiotherapy to
             thorax measurable lesions or consolidation radiotherapy).

          8. Agree to use double-barrier contraception (males and females alike [if applicable]). A
             negative pregnancy test must be documented at Screening for females of childbearing
             potential.

             Note: Females of childbearing potential are defined as those women with less than 2
             years after last menstruation and not surgically sterile, while post-menopausal refers
             to those women with at least 2 years from last menstruation.

          9. Have signed a voluntary written informed consent form (ICF). Patients should be
             cooperative, willing and able to participate and adhere to the Protocol requirements,
             including their availability for the follow-up.

        Exclusion Criteria:

          1. Patient has no measurable disease (as defined by RECIST Criteria, version 1.1).

          2. Patient has EGF-R mutation.

          3. Patient has EGF serum concentration below required threshold.

          4. Patient is a candidate for concurrent chemo-radiotherapy or post chemo thoracic
             radiotherapy.

          5. Patient has a history of known or suspected central nervous system (CNS) metastases.

          6. Patient has a history of primary malignancy (except resected non-melanoma skin cancer
             or curatively treated carcinoma in situ of the cervix), unless in complete remission
             and off all chemotherapy and/or radiotherapy for that disease for a minimum of 5
             years. Any palliative radiotherapy to alleviate pain in bone metastases is permitted.

          7. Patient is taking immunosuppressant drugs such as azathioprine, tacrolimus,
             cyclosporine, etc. Use is not permitted within 1 month before Screening.

          8. Patient is taking any other immunotherapy.

          9. Patient has primary or secondary immunodeficiencies (e.g. documented Human
             Immunodeficiency Virus [HIV]).

         10. Patient has autoimmune disease.

         11. Patient has undergone splenectomy.

         12. Patient is taking oral, intramuscular or intravenous corticosteroids. Use is not
             permitted within 1 month before Screening. Inhaled corticosteroids to treat
             respiratory insufficiency (e.g. chronic obstructive pulmonary disease [COPD]), or
             topical steroids are permitted.

         13. Patient has neurotoxicity (Grade ≥2).

         14. Patient has diarrhoea (Grade ≥2).

         15. Patient has received other vaccines (with the exception of the influenza vaccine),
             within 1 month before Screening.

         16. Patient has a history of any severe or life-threatening hypersensitivity reaction.

         17. Patient has an unstable systemic disease (including active infection, uncontrolled
             hypertension, unstable angina, congestive heart failure, myocardial infarction within
             the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal and
             metabolic disease).

         18. Patient has recent history (within 6 months before Screening) of chronic alcohol or
             drug abuse which may compromise the patient's safety or ability to participate in
             study activities.

         19. Patient has a history of psychiatric disorder that prevents patients from providing
             informed consent or following Protocol instructions.

         20. Patient is currently enrolled in an investigational device or drug trial, or <1 month
             since completing an investigational device or drug trial.

         21. Female patients who are pregnant or lactating.

         22. Patient has any other factor that in the opinion of the Investigator (or designee)
             would make the patient unsafe or unsuitable for the study.